Latest News and Press Releases

Histogen has filed for voluntary Chapt. 11 protection to maximize share offering

Meeting Adjourned for a Final Time to January 4, 2024 at 8:00 a.m. PTPotential Estimated Cash Distribution to Shareholders of $0.30 to $0.41 if Dissolution Proposal Approved SAN DIEGO, Dec. 14, 2023...

SAN DIEGO, Dec. 05, 2023 (GLOBE NEWSWIRE) -- Histogen Inc. (OTC: HSTO) today announced that its special meeting of stockholders (the “Special Meeting”) has been adjourned to Thursday, December 14,...

SAN DIEGO, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), today announced that its Board of Directors, after extensive consideration of potential strategic alternatives, has...

SAN DIEGO, July 05, 2023 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class clinical and preclinical small...

Received FDA Clearance of IND Application for Emricasan for the Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Emricasan Treatment has Therapeutic Effect Against...

Emricasan Treatment has Therapeutic Effect Against Bacterial Skin Infection in Mice Pipeline Focus on Pan-Caspase and Caspase Selective Inhibitors for Infectious and Inflammatory Diseases ...

Licensed Patents Expected to Provide Freedom to Operate and Exclusivity for Emricasan Pipeline Focus on Pan-Caspase and Caspase Selective Inhibitors for Infectious and Inflammatory Diseases ...

The Newly Issued Patent is Expected to Provide Protection into 2040 Pipeline Focus on Pan-Caspase and Caspase Selective Inhibitors for Infectious and Inflammatory Diseases SAN DIEGO, March 16, 2023...

SAN DIEGO, March 09, 2023 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company on developing potential first-in-class clinical and preclinical small molecule...